ArticleESC heart failure2023
Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Effects of Ferric Derisomaltose in Heart Failure with Iron Deficiency according to Renal Function in the IRONMAN Randomised Controlled Trial.American journal of nephrology · 2026Trial
- Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.European heart journal · 2024Trial
- Review
- Iron deficiency in heart failure: news and pitfalls in 2025.ESC heart failure · 2026Article
- Expert Perspectives on Managing Iron Deficiency in People with CKD and/or HF.Journal of clinical medicine · 2026Article
- Association between serum transferrin and overall survival in cancer patients: a multi-center cohort study.BMC cancer · 2026Observational
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Prognostic impact of iron deficiency in new-onset chronic heart failure: Danish Heart Failure Registry insights.ESC heart failure · 2025Article
- Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities.ESC heart failure · 2025Article
- [Iron deficiency in cardiovascular disease].Innere Medizin (Heidelberg, Germany) · 2024Review
- Clinical characteristics and prognosis analysis of pseudomonas aeruginosa bloodstream infection in adults: a retrospective study.Clinical and experimental medicine · 2024Article
- Treating iron deficiency in patients with heart failure: what, why, when, how, where and who.Heart (British Cardiac Society) · 2024Review
- Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Defining iron deficiency in patients with heart failure.Nature reviews. Cardiology · 2024Article
- Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure.ESC heart failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
aimsTransferrin saturation (TSAT), a marker of iron deficiency, reflects both serum concentrations of iron (SIC) and transferrin (STC). TSAT is susceptible to changes in each of these biomarkers. Little is known about determinants of STC and its influence on TSAT and mortality in patients with heart failure. Accordingly, we studied the relationship of STC to clinical characteristics, to markers of iron deficiency and inflammation and to mortality in chronic heart failure (CHF). METHODS AND
resultsProspective cohort of patients with CHF attending a clinic serving a large local population. A total of 4422 patients were included (median age 75 (68-82) years; 40% women; 32% with left ventricular ejection fraction ≤40%). STC ≤ 2.3 g/L (lowest quartile) was associated with older age, lower SIC and haemoglobin and higher high-sensitivity C-reactive protein, ferritin and N-terminal pro-brain natriuretic peptide compared with those with STC > 2.3 g/L. In the lowest STC quartile, 624 (52%) patients had SIC ≤13 μmol/L, of whom 38% had TSAT ≥20%. For patients in the highest STC quartile, TSAT was <20% when SIC was >13 μmol/L in 185 (17%) patients. STC correlated inversely with ferritin (r = -0.52) and high-sensitivity C-reactive protein (r = -0.17) and directly with albumin (r = 0.29); all P < 0.001. In models adjusted for age, N-terminal pro-brain natriuretic peptide and haemoglobin, both higher SIC (hazard ratio 0.87 [95% CI: 0.81-0.95]) and STC (hazard ratio 0.82 [95% CI: 0.73-0.91]) were associated with lower mortality. SIC was more strongly associated with both anaemia and mortality than either STC or TSAT.
conclusionsMany patients with CHF and a low STC have low SIC even when TSAT is >20% and serum ferritin >100 μg/L; such patients have a high prevalence of anaemia and a poor prognosis and might have iron deficiency but are currently excluded from clinical trials of iron repletion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.